| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Y Nagata, KH Lan, X Zhou, M Tan, FJ Esteva, AA Sahin, KS Klos, P Li, ... Cancer cell 6 (2), 117-127, 2004 | 2240 | 2004 |
| Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation H Zhou, J Kuang, L Zhong, W Kuo, J Gray, A Sahin, B Brinkley, S Sen Nature genetics 20 (2), 189-193, 1998 | 1619 | 1998 |
| Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in … AU Buzdar, NK Ibrahim, D Francis, DJ Booser, ES Thomas, RL Theriault, ... Journal of clinical oncology 23 (16), 3676-3685, 2005 | 1488 | 2005 |
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ... Cancer research 68 (15), 6084-6091, 2008 | 1188 | 2008 |
| Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth L Zhang, S Zhang, J Yao, FJ Lowery, Q Zhang, WC Huang, P Li, M Li, ... Nature 527 (7576), 100-104, 2015 | 1153 | 2015 |
| Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics BT Hennessy, AM Gonzalez-Angulo, K Stemke-Hale, MZ Gilcrease, ... Cancer research 69 (10), 4116-4124, 2009 | 1041 | 2009 |
| Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity CW Li, SO Lim, W Xia, HH Lee, LC Chan, CW Kuo, KH Khoo, SS Chang, ... Nature communications 7 (1), 12632, 2016 | 870 | 2016 |
| IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway DF Lee, HP Kuo, CT Chen, JM Hsu, CK Chou, Y Wei, HL Sun, LY Li, ... Cell 130 (3), 440-455, 2007 | 811 | 2007 |
| ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation JY Yang, CS Zong, W Xia, H Yamaguchi, Q Ding, X Xie, JY Lang, CC Lai, ... Nature cell biology 10 (2), 138-148, 2008 | 789 | 2008 |
| Benign breast diseases: classification, diagnosis, and management M Guray, AA Sahin The oncologist 11 (5), 435-449, 2006 | 702 | 2006 |
| Deubiquitination and stabilization of PD-L1 by CSN5 SO Lim, CW Li, W Xia, JH Cha, LC Chan, Y Wu, SS Chang, WC Lin, ... Cancer cell 30 (6), 925-939, 2016 | 633 | 2016 |
| AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer KM Vasudevan, DA Barbie, MA Davies, R Rabinovsky, CJ McNear, ... Cancer cell 16 (1), 21-32, 2009 | 615 | 2009 |
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ... Nature medicine 17 (4), 461-469, 2011 | 606 | 2011 |
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor … AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ... Clinical Cancer Research 13 (1), 228-233, 2007 | 596 | 2007 |
| Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance E Devarajan, AA Sahin, JS Chen, RR Krishnamurthy, N Aggarwal, ... Oncogene 21 (57), 8843-8851, 2002 | 554 | 2002 |
| High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller AM Gonzalez-Angulo, JK Litton, KR Broglio, F Meric-Bernstam, R Rakkhit, ... Journal of clinical oncology 27 (34), 5700, 2009 | 549 | 2009 |
| The 2019 WHO classification of tumours of the breast PH Tan, I Ellis, K Allison, E Brogi, SB Fox, S Lakhani, AJ Lazar, EA Morris, ... Histopathology 77 (2), 2020 | 539 | 2020 |
| Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ E Half, XM Tang, K Gwyn, A Sahin, K Wathen, FA Sinicrope Cancer research 62 (6), 1676-1681, 2002 | 531 | 2002 |
| Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks MC Green, AU Buzdar, T Smith, NK Ibrahim, V Valero, MF Rosales, ... Journal of Clinical Oncology 23 (25), 5983-5992, 2005 | 509 | 2005 |
| Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy BT Hennessy, GN Hortobagyi, R Rouzier, H Kuerer, N Sneige, AU Buzdar, ... Journal of Clinical Oncology 23 (36), 9304-9311, 2005 | 490 | 2005 |
